ProStrakan Secures Offer From Japan's Kyowa Hakko, But Analysts Say Too Low
This article was originally published in PharmAsia News
Three months after putting itself up for sale, U.K.-based specialty pharma firm ProStrakan Group PLC on Feb. 21 announced a cash offer from Japan's Kyowa Hakko Kirin Co. Ltd. The 130 pence-per-share deal values the company at about £292 million ($475 million)
You may also be interested in...
A second U.S. product approval in two weeks, plus a partner-driven re-financing, means the price of ProStrakan just went up.
The specialty pharma company is 'evaluating interest' from buyers after delays to key drugs.
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).